Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

PrenaTest® is Now Applicable for Multiple Pregnancies

Published: Tuesday, February 11, 2014
Last Updated: Tuesday, February 11, 2014
Bookmark and Share
To be generally applied after IVF, egg donation and other infertility treatments.

As Europe’s first non-invasive molecular diagnostic blood test for the determination of fetal chromosomal aneuploidies from maternal blood, PrenaTest® has now successfully been validated for use in multiple pregnancies.

It is the only blood test that can be used without any restriction following all methods of fertility treatment, such as IVF or egg donation, after the 9th week of gestation.

To date, several thousand PrenaTest® analysis have been successfully performed in singleton pregnancies.

The number of multiple pregnancies has steadily increased in Germany over the last years due to an increased use of fertility treatments especially with women of higher age.

For these, PrenaTest® is a valuable and risk-free improvement for the determination of fetal chromosomal aneuploidies given the significantly increased risk for miscarriage following an invasive diagnostic procedure like amniocentesis, compared to such risk in case of singleton pregnancies.

In addition, conventional non-invasive examinations such as first trimester screening show a two to three fold increase with respect to the false positive rate.

"We are happy to report that we correctly classified all trisomy cases with the PrenaTest® in a validation study which included 62 twin and triplet pregnancies,” said Dr. Michael Lutz , CEO of LifeCodexx AG. "With the successful validation of the PrenaTest® for multiple pregnancies, we have set high standards again in this innovative field of non-invasive prenatal diagnosis."

In addition, the innovative PrenaTest® express is now available in other European countries, too. This express version of the PrenaTest® provides the test results in one week and thus shortens the stressful waiting period for pregnant women to a minimum. In Germany about every fourth patient opts for the express version.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PrenaTest® is Now Reimbursed by Swiss Statutory Health Insurance Programs
The first reimbursement worldwide of non-invasive prenatal tests by a national healthcare system.
Wednesday, July 08, 2015
Improved PrenaTest® Provides Early Knowledge for High Risk Pregnancies
PrenaTest® can now be performed after the ninth week of pregnancy.
Wednesday, July 10, 2013
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos